Little Unexpected But I’ll take it Not sure how Thrm placed top 3 in life sciences for the top performers of 2022 tsc, but I'll take it I guess, and the fact that Fia mentions as recently as today about the acuvid moving its way through FDA shows his confidence in the product, which is also a positive. I was starting to think he was trying to overshadow Acuvid with these other product placements in the PRs, for cold sores etc, but for your company to get spotlight on yahoo finance for a good thing, I'm glad he publicly talked about his antigen test and not some other b.s thrm is working on, no one would publicize bad products in such a setting. Hopefully submission news is SOON enough.
Good on you Fia! IMHO GL TO ALL